TIM-3/Gal-9 interaction induces IFNγ-dependent IDO1 expression in acute myeloid leukemia blast cells

被引:53
作者
Folgiero, Valentina [1 ]
Cifaldi, Loredana [1 ]
Pira, Giuseppina Li [1 ]
Goffredo, Bianca Maria [2 ]
Vinti, Luciana [1 ]
Locatelli, Franco [1 ,3 ]
机构
[1] IRCCS Bambino Gesu Childrens Hosp, Dept Pediat Hematol & Oncol, I-00146 Rome, Italy
[2] IRCCS Bambino Gesu Childrens Hosp, Dept Lab Med, I-00146 Rome, Italy
[3] Univ Pavia, Dept Pediat Sci, I-27100 Pavia, Italy
来源
JOURNAL OF HEMATOLOGY & ONCOLOGY | 2015年 / 8卷
基金
新加坡国家研究基金会;
关键词
AML; IDO1; Immune escape; NK cells; Galectin-9; RECOMBINANT HUMAN THROMBOPOIETIN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; REFRACTORY MULTIPLE-MYELOMA; PROGENITOR CELLS; IN-VITRO; RECEPTOR MPL; HEMATOLOGICAL MALIGNANCIES; PROTEASOME INHIBITORS; STIMULATING AGENTS; PERIPHERAL-BLOOD;
D O I
10.1186/s13045-015-0134-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
NK cells expressing TIM-3 show a marked increase in IFN gamma production in response to acute myeloid leukemia (AML) blast cells that endogenously express Gal-9. Herein, we demonstrate that NK cell-mediated production of IFN gamma, induced by TIM-3/Gal-9 interaction and released in bone marrow microenvironment, is responsible for IDO1 expression in AML blasts. IDO1-expressing AML blasts consequently down-regulate NK cell degranulation activity, by sustaining leukemia immune escape. Furthermore, the blocking of TIM-3/Gal-9 interaction strongly down-regulates IFN gamma-dependent IDO1 activity. Thus, the inhibition of TIM-3/Gal-9 immune check point, which affects NK cell-dependent IFN gamma production and the consequent IDO1 activation, could usefully integrate current chemotherapeutic approaches.
引用
收藏
页数:5
相关论文
共 35 条
  • [1] Adams J, 1999, CANCER RES, V59, P2615
  • [2] IDENTIFICATION AND CLONING OF A MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR THAT IS A LIGAND FOR THE CYTOKINE RECEPTOR MPL
    BARTLEY, TD
    BOGENBERGER, J
    HUNT, P
    LI, YS
    LU, HS
    MARTIN, F
    CHANG, MS
    SAMAL, B
    NICHOL, JL
    SWIFT, S
    JOHNSON, MJ
    HSU, RY
    PARKER, VP
    SUGGS, S
    SKRINE, JD
    MEREWETHER, LA
    CLOGSTON, C
    HSU, E
    HOKOM, MM
    HORNKOHL, A
    CHOI, E
    PANGELINAN, M
    SUN, Y
    MAR, V
    MCNINCH, J
    SIMONET, L
    JACOBSEN, F
    XIE, C
    SHUTTER, J
    CHUTE, H
    BASU, R
    SELANDER, L
    TROLLINGER, D
    SIEU, L
    PADILLA, D
    TRAIL, G
    ELLIOTT, G
    IZUMI, R
    COVEY, T
    CROUSE, J
    GARCIA, A
    XU, W
    DELCASTILLO, J
    BIRON, J
    COLE, S
    HU, MCT
    PACIFICI, R
    PONTING, I
    SARIS, C
    WEN, D
    [J]. CELL, 1994, 77 (07) : 1117 - 1124
  • [3] Effects of recombinant human thrombopoietin alone and in combination with erythropoietin and early-acting cytokines on human mobilized purified CD34(+) progenitor cells cultured in serum-depleted medium
    Birkmann, J
    Oez, S
    Smetak, M
    Kaiser, G
    Kappauf, H
    Gallmeier, WM
    [J]. STEM CELLS, 1997, 15 (01) : 18 - 32
  • [4] Ex vivo expansion of megakaryocyte progenitor cells from normal bone marrow and peripheral blood and from patients with haematological malignancies
    Blair, A
    Baker, CL
    Pamphilon, DH
    Judson, PA
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2002, 116 (04) : 912 - 919
  • [5] Thrombopoietin, but not erythropoietin promotes viability and inhibits apoptosis of multipotent murine hematopoietic progenitor cells in vitro
    Borge, OJ
    Ramsfjell, V
    Veiby, OP
    Murphy, MJ
    Lok, S
    Jacobsen, SEW
    [J]. BLOOD, 1996, 88 (08) : 2859 - 2870
  • [6] Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura
    Bussel, James B.
    Cheng, Gregory
    Saleh, Mansoor N.
    Psaila, Bethan
    Kovaleva, Lidia
    Meddeb, Balkis
    Kloczko, Janusz
    Hassani, Habib
    Mayer, Bhabita
    Stone, Nicole L.
    Arning, Michael
    Provan, Drew
    Jenkins, Julian M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (22) : 2237 - 2247
  • [7] Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial
    Bussel, James B.
    Provan, Drew
    Shamsi, Tahir
    Cheng, Gregory
    Psaila, Bethan
    Kovaleva, Lidia
    Salama, Abdulgabar
    Jenkins, Julian M.
    Roychowdhury, Debasish
    Mayer, Bhabita
    Stone, Nicole
    Arning, Michael
    [J]. LANCET, 2009, 373 (9664) : 641 - 648
  • [8] Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
    Dimopoulos, Meletios
    Spencer, Andrew
    Attal, Michael
    Prince, H. Miles
    Harousseau, Jean-Luc
    Dmoszynska, Anna
    San Miguel, Jesus
    Hellmann, Andrzej
    Facon, Thierry
    Foa, Robin
    Corso, Alessandro
    Masliak, Zvenyslava
    Olesnyckyj, Marta
    Yu, Zhinuan
    Patin, John
    Zeldis, Jerome B.
    Knight, Robert D.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (21) : 2123 - 2132
  • [9] Drexler HG, 1996, LEUKEMIA, V10, P1405
  • [10] Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function
    Erhardt, Joseph A.
    Erickson-Miller, Connie L.
    Aivado, Manuel
    Abboud, Melanie
    Pillarisetti, Kodandaram
    Toomey, John R.
    [J]. EXPERIMENTAL HEMATOLOGY, 2009, 37 (09) : 1030 - 1037